Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)

被引:1
|
作者
Soliemanabad, Saeed Kargar [1 ]
Rasouli, Kimia [1 ]
Zakariaei, Zakaria [2 ,3 ]
Soleymani, Mostafa [3 ]
Aliabadi, Parastoo Karimi [4 ]
机构
[1] Mazandaran Univ Med Sci, Student Res Comm, Sari, Iran
[2] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Toxoplasmosis Res Ctr, Toxicol & Forens Med Div, POB 48166-33131, Sari, Iran
[3] Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Iranian Natl Registry Ctr Lophomoniasis & Toxopla, Communicable Dis Inst, Sari, Iran
[4] Mazandaran Univ Med Sci, Diabet Res Ctr, Dept Family Med, Sari, Iran
来源
关键词
Atorvastatin; Warfarin; Drug interaction; Rhabdomyolysis; ACUTE KIDNEY INJURY;
D O I
10.1016/j.amsu.2022.103384
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Although atorvastatin has serious adverse effects, including hepatotoxicity and myopathy, it can cause drug interactions and side effects such as rhabdomyolysis and acute kidney injury, especially when combined with warfarin, which uses the same enzyme pathway for metabolism. Case presentation: We describe a 66-year-old man with a history of ischemic heart disease who developed renal complications and rhabdomyolysis after concomitant use of atorvastatin and warfarin. Discussion: Statins reduce serum LDL cholesterol levels significantly. It is a safe and cost-effective medicine used in the treatment of DLP as well as the primary and secondary prevention of CAD, atherosclerosis, myocardial infarction, and stroke. Despite their benefits, statins can cause side effects in various organs of the body, including the gastrointestinal tract, CNS, liver, and kidneys. Conclusion: Statins are widely prescribed to patients with cardiovascular problems. Therefore, clinicians should pay attention to the patient's medical history, current prescribed doses, and drug interactions when adding new drugs or adjusting existing drugs.
引用
收藏
页数:3
相关论文
共 50 条
  • [31] Influence of atorvastatin on erythrocyte membranes in patients with ischemic heart disease
    Storozhok, M. A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 195 - 195
  • [32] Eye Bleeding Due to Leech Infestation in an Ischemic Heart-Disease Patient
    Shirzadeh, E.
    Golmohammadi, R.
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2012, 14 (04) : 245 - 247
  • [33] Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease
    Mikhin, V. P.
    Zhilyaeva, Yu. A.
    Gromnacky, N. I.
    KARDIOLOGIYA, 2016, 56 (05) : 42 - 46
  • [34] Possible antiretroviral therapy-warfarin drug interaction
    Fulco, Patricia Pecora
    Zingone, Michelle M.
    Higginson, Robert T.
    PHARMACOTHERAPY, 2008, 28 (07): : 945 - 949
  • [35] RHABDOMYOLYSIS INDUCED BY THE CIPROFIBRATE-MICONAZOLE COMBINATION - A NEW DRUG-DRUG INTERACTION
    CLEAU, D
    HUMBLOT, S
    JOBARD, JM
    DELACOUR, JL
    FLORIOT, C
    WAGSCHAL, G
    DAOUDAL, P
    ORY, JP
    SEMAINE DES HOPITAUX, 1995, 71 (31-32): : 966 - 968
  • [37] A Rare Presentation of Acute Renal Failure Secondary to Rhabdomyolysis in a Patient Due to Atorvastatin Requiring Short-Term Renal Replacement Therapy
    Khan, Zahid
    Ibekwe, Mildred
    Abumedian, Mohammed
    Yousif, Yousif
    Mlawa, Gideon
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
  • [38] Monitoring unbound warfarin in drug combination therapy by pharmacokinetics and fluorospectrometry
    Jia-ding Guo
    Ying-yue Zhang
    Yan Huo
    Yan-xu Chang
    Er-wei Liu
    Jia Hao
    Chinese Herbal Medicines, 2019, (01) : 92 - 97
  • [39] Monitoring unbound warfarin in drug combination therapy by pharmacokinetics and fluorospectrometry
    Guo, Jia-ding
    Zhang, Ying-yue
    Huo, Yan
    Chang, Yan-xu
    Liu, Er-wei
    Hao, Jia
    CHINESE HERBAL MEDICINES, 2019, 11 (01) : 92 - 97